摘要
目的检测肺癌患者血D-二聚体的改变，了解它与肿瘤发展、扩散、预后及疗效的关系。方法检测肺癌患者359例，其中305例为带瘤患者，54例术后2a无复发、转移，分析其血D-二聚体水平在不同分期、病理类型及治疗过程中的异常改变。结果305例肺癌患者的血D-二聚体水平显著高于正常对照组和54例术后无复发、转移患者，且随着肿瘤发展和扩散、转移明显升高；23例小细胞肺癌患者临床治愈时的血D-二聚体水平明显低于疗前和复发时；不同病理类型肺癌患者血D-二聚体水平在局限期和扩散期无明显差异。结论肺癌患者早期就有血D-二聚体的异常升高，其血D-二聚体的异常改变对病情的发展、预后及疗效有重要意义；不同病理类型肺癌的血D-二聚体水平无明显差异。
Objective To evaluate the variations of the plasma D-dimer as a possible marker of the outcome of lung cancer and the curative effect. Methods The D-dimer was measured in 359 cases of lung cancers, 305 with different phase and histologic type, 54 with lung cancer resection two years before (no recurrence and no metastases). Then, the different series were compared with each other and control group (a health group and another group with chronic obstructive plumonary disease). Results The D-dimer of 305 lung cancers significantly increased compared with control group and 54 with lung cancer resection (no recurrence and no metastases), and rose following seriousness of clinical phase. The D-dimer in 23 small cell carcinomas were significantly lower in clinical cureness than before treatment and recurrence. Conclusion These data indicated that there was significant elevation of D-dimer in lung cancer from the early clinical stage of the disease. The elevation of the D-dimer was associated with the size of tumor and occurrence of metastasis. The variations of the D-Dimer have a high value in the prognosis and the curative effect of lung cancer. In addition, there appears to be the same levels of clotting activation according to histologic type of tumor.
出处
《中国实验诊断学》
1999年第4期158-159,共2页
Chinese Journal of Laboratory Diagnosis
